Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Gastrointestinal 1

Conditions

Medication Adherence 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Cyclophosphamide 259fludarabine phosphate 232Azacitidine 180fludarabine 179Busulfan 174Cytarabine 154Mycophenolic Acid 147Tacrolimus 145Whole-Body Irradiation 141Imatinib Mesylate 141Peripheral Blood Stem Cell Transplantation 139Cyclosporine 110Antilymphocyte Serum 108Melphalan 106Methotrexate 105Filgrastim 101Decitabine 98nilotinib 82venetoclax 77ruxolitinib 72Granulocyte Colony-Stimulating Factor 66Stem Cell Transplantation 62Dasatinib 62Thiotepa 60Radiotherapy 60thymoglobulin 52Specimen Handling 49Etoposide 49Clofarabine 46Cord Blood Stem Cell Transplantation 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Pharmaceutical Services × Myeloid × Clear all
NCT03090477 2019-04-05

Impact of a Pharmaceutical Care Model in the Management of Chronic Myeloid Leukemia Patients

UCSI University

Phase NA Completed
129 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Medication Adherence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡